Trial Profile
Evaluation of the usefulness of anti-cholinergic and B(Beta)3 agonist in patients with OAB.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Imidafenacin (Primary) ; Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms SORT
- 11 Oct 2012 New trial record
- 01 Oct 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.